Literature DB >> 30006681

Molecular biology as a tool for the treatment of cancer.

Carla de Castro Sant' Anna1,2, Alberto Gomes Ferreira Junior3, Paulo Soares3, Fabricio Tuji3, Eric Paschoal3, Luiz Cláudio Chaves3, Rommel Rodriguez Burbano3.   

Abstract

Cancer is a genetic disease characterized by uncontrolled cell growth and metastasis. Cancer can have a number of causes, such the activation of oncogenes, the inactivation of tumor-suppressing genes, mutagenesis provoked by external factors, and epigenetic modifications. The development of diagnostic tools and treatments using a molecular biological approach permits the use of sensitive, low-cost, noninvasive tests for cancer patients. Biomarkers can be used to provide rapid, personalized oncology, in particular the molecular diagnosis of chronic myeloid leukemia, and gastric, colon, and breast cancers. Molecular tests based on DNA methylation can also be used to direct treatments or evaluate the toxic effects of chemotherapy. The adequate diagnosis, prognosis, and prediction of the response of cancer patients to treatment are essential to ensure the most effective therapy, reduce the damaging effects of treatment, and direct the therapy to specific targets, and in this context, molecular biology has become increasingly important in oncology. In this brief review, we will demonstrate the fundamental importance of molecular biology for the treatment of three types of cancer-chronic myeloid leukemia, hereditary diffuse gastric cancer, and astrocytomas (sporadic tumors of the central nervous system). In each of these three models, distinct biological mechanisms are involved in the transformation of the cells, but in all cases, molecular biology is fundamental to the development of personalized analyses for each patient and each type of neoplasia, and to guarantee the success of the treatment.

Entities:  

Keywords:  Biomarkers; Cancer; Epigenetics; Molecular biology

Mesh:

Substances:

Year:  2018        PMID: 30006681     DOI: 10.1007/s10238-018-0518-1

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  95 in total

1.  THEODOR BOVERI.

Authors:  F BALTZER
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

Review 2.  Overview: genes that predispose to cancer.

Authors:  A G Knudson
Journal:  Mutat Res       Date:  1991-04       Impact factor: 2.433

Review 3.  Significance of multiple mutations in cancer.

Authors:  K R Loeb; L A Loeb
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

Review 4.  Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  O N Witte
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

5.  Theodor Boveri and the origin of malignant tumours.

Authors:  K L Manchester
Journal:  Trends Cell Biol       Date:  1995-10       Impact factor: 20.808

6.  The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.

Authors:  Vivian Barak; Amichay Meirovitz; Vera Leibovici; Jacob Rachmut; Tamar Peretz; Ron Eliashar; Menachem Gross
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

Review 7.  The multistep nature of cancer.

Authors:  B Vogelstein; K W Kinzler
Journal:  Trends Genet       Date:  1993-04       Impact factor: 11.639

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  The sequence of the human genome.

Authors:  J C Venter; M D Adams; E W Myers; P W Li; R J Mural; G G Sutton; H O Smith; M Yandell; C A Evans; R A Holt; J D Gocayne; P Amanatides; R M Ballew; D H Huson; J R Wortman; Q Zhang; C D Kodira; X H Zheng; L Chen; M Skupski; G Subramanian; P D Thomas; J Zhang; G L Gabor Miklos; C Nelson; S Broder; A G Clark; J Nadeau; V A McKusick; N Zinder; A J Levine; R J Roberts; M Simon; C Slayman; M Hunkapiller; R Bolanos; A Delcher; I Dew; D Fasulo; M Flanigan; L Florea; A Halpern; S Hannenhalli; S Kravitz; S Levy; C Mobarry; K Reinert; K Remington; J Abu-Threideh; E Beasley; K Biddick; V Bonazzi; R Brandon; M Cargill; I Chandramouliswaran; R Charlab; K Chaturvedi; Z Deng; V Di Francesco; P Dunn; K Eilbeck; C Evangelista; A E Gabrielian; W Gan; W Ge; F Gong; Z Gu; P Guan; T J Heiman; M E Higgins; R R Ji; Z Ke; K A Ketchum; Z Lai; Y Lei; Z Li; J Li; Y Liang; X Lin; F Lu; G V Merkulov; N Milshina; H M Moore; A K Naik; V A Narayan; B Neelam; D Nusskern; D B Rusch; S Salzberg; W Shao; B Shue; J Sun; Z Wang; A Wang; X Wang; J Wang; M Wei; R Wides; C Xiao; C Yan; A Yao; J Ye; M Zhan; W Zhang; H Zhang; Q Zhao; L Zheng; F Zhong; W Zhong; S Zhu; S Zhao; D Gilbert; S Baumhueter; G Spier; C Carter; A Cravchik; T Woodage; F Ali; H An; A Awe; D Baldwin; H Baden; M Barnstead; I Barrow; K Beeson; D Busam; A Carver; A Center; M L Cheng; L Curry; S Danaher; L Davenport; R Desilets; S Dietz; K Dodson; L Doup; S Ferriera; N Garg; A Gluecksmann; B Hart; J Haynes; C Haynes; C Heiner; S Hladun; D Hostin; J Houck; T Howland; C Ibegwam; J Johnson; F Kalush; L Kline; S Koduru; A Love; F Mann; D May; S McCawley; T McIntosh; I McMullen; M Moy; L Moy; B Murphy; K Nelson; C Pfannkoch; E Pratts; V Puri; H Qureshi; M Reardon; R Rodriguez; Y H Rogers; D Romblad; B Ruhfel; R Scott; C Sitter; M Smallwood; E Stewart; R Strong; E Suh; R Thomas; N N Tint; S Tse; C Vech; G Wang; J Wetter; S Williams; M Williams; S Windsor; E Winn-Deen; K Wolfe; J Zaveri; K Zaveri; J F Abril; R Guigó; M J Campbell; K V Sjolander; B Karlak; A Kejariwal; H Mi; B Lazareva; T Hatton; A Narechania; K Diemer; A Muruganujan; N Guo; S Sato; V Bafna; S Istrail; R Lippert; R Schwartz; B Walenz; S Yooseph; D Allen; A Basu; J Baxendale; L Blick; M Caminha; J Carnes-Stine; P Caulk; Y H Chiang; M Coyne; C Dahlke; A Deslattes Mays; M Dombroski; M Donnelly; D Ely; S Esparham; C Fosler; H Gire; S Glanowski; K Glasser; A Glodek; M Gorokhov; K Graham; B Gropman; M Harris; J Heil; S Henderson; J Hoover; D Jennings; C Jordan; J Jordan; J Kasha; L Kagan; C Kraft; A Levitsky; M Lewis; X Liu; J Lopez; D Ma; W Majoros; J McDaniel; S Murphy; M Newman; T Nguyen; N Nguyen; M Nodell; S Pan; J Peck; M Peterson; W Rowe; R Sanders; J Scott; M Simpson; T Smith; A Sprague; T Stockwell; R Turner; E Venter; M Wang; M Wen; D Wu; M Wu; A Xia; A Zandieh; X Zhu
Journal:  Science       Date:  2001-02-16       Impact factor: 47.728

10.  Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.

Authors:  Anna Kazarian; Oleg Blyuss; Gergana Metodieva; Aleksandra Gentry-Maharaj; Andy Ryan; Elena M Kiseleva; Olga M Prytomanova; Ian J Jacobs; Martin Widschwendter; Usha Menon; John F Timms
Journal:  Br J Cancer       Date:  2017-01-12       Impact factor: 7.640

View more
  10 in total

1.  Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.

Authors:  Nataliya Babyshkina; Sergey Vtorushin; Tatyana Dronova; Stanislav Patalyak; Elena Slonimskaya; Julia Kzhyshkowska; Nadejda Cherdyntseva; Evgeny Choynzonov
Journal:  Clin Exp Med       Date:  2019-09-27       Impact factor: 3.984

2.  miR-887-3p Inhibits the Progression of Colorectal Cancer via Downregulating DNMT1 Expression and Regulating P53 Expression.

Authors:  Da Teng; Shaoyou Xia; Shidong Hu; Yang Yan; Boyan Liu; Yu Yang; Xiaohui Du
Journal:  Comput Intell Neurosci       Date:  2022-06-27

3.  Genomics Score Based on Genome-Wide Network Analysis for Prediction of Survival in Gastric Cancer: A Novel Prognostic Signature.

Authors:  Zepang Sun; Hao Chen; Zhen Han; Weicai Huang; Yanfeng Hu; Mingli Zhao; Tian Lin; Jiang Yu; Hao Liu; Yuming Jiang; Guoxin Li
Journal:  Front Genet       Date:  2020-08-06       Impact factor: 4.599

4.  Integrated bioinformatic analysis of HNF1A in human cancers.

Authors:  Enfan Zhang; Xi Huang; Jingsong He
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

5.  Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.

Authors:  Sandra Mara Burin; Maira da Costa Cacemiro; Juçara Gastaldi Cominal; Rone Aparecido De Grandis; Ana Rita Thomazela Machado; Flavia Sacilotto Donaires; Adelia Cristina Oliveira Cintra; Luciana Ambrosio; Lusânia Maria Greggi Antunes; Suely Vilela Sampaio; Fabíola Attié de Castro
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-12-14

6.  microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.

Authors:  Kexin Jiang; Huawei Zou
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

7.  LEM domain containing 1 (LEMD1) transcriptionally activated by SRY-related high-mobility-group box 4 (SOX4) accelerates the progression of colon cancer by upregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.

Authors:  Ding Li; Ding Wang; Haofeng Liu; Xiaohui Jiang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 8.  Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms.

Authors:  Mariusz Z Ratajczak; Kamila Bujko; Aaron Mack; Magda Kucia; Janina Ratajczak
Journal:  Leukemia       Date:  2018-10-30       Impact factor: 11.528

9.  A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).

Authors:  Eleni Papakonstantinou; Dimitrios Vlachakis; Trias Thireou; Panayiotis G Vlachoyiannopoulos; Elias Eliopoulos
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

10.  Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.

Authors:  Brooke E Sanders; Lisa Ku; Paul Walker; Benjamin G Bitler
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.